Kornimate/medical-research-clean huggingface dataset:
an online survey to understand feelings related to covid-19 among ilbs patients with liver disease

Conditions: COVID 19

Summary: the current outbreak of covid-19 pandemic has been marked by severe psychological problems. people around the world experienced a similarly frightening public health emergency, on a global scale, with the spread of this corona infection. (1) studies of the severe acute respiratory syndrome (sars) outbreaks that occurred in canada, taiwan, and hong kong found that the enormous emotional burden carried by those health care workers who were on the front lines of the battle against the disease led to psychological morbidity like anxiety, stress and even further leads to post traumatic stress disorder. the initial phase of the covid-19 outbreak in china in 2020 also reported more than half of the respondents rated the psychological impact as moderate-to-severe, and about one-third reported moderate-to-severe anxiety in general population.(2) - the chances of fear, anxiety and stress are even higher in individuals with preexisting liver disease as they have restriction of services for getting treatment. moreover, they can have the following additional issues: * fear of severe form of corona present (as presented in most of the media and research) * fear of dying * added uncertainty * family members also worried

* as the indian government recommended the public to minimize face-to-face interaction and isolate them at home, potential respondents will be invited through a text message which will lead to a survey monkey page (designed by it team at ilbs, new delhi). * all people who have shown at ilbs (1st january 2018 - 31st march 2020), will be sent the sms for participation. they will be asked to provide phone numbers for retrieval of their child-turcotte-pugh (ctp) and model for end stage liver disease (meld) scores from hospital records. patients with education more than 10th standard (or able to understand / read english) will only proceed with the survey. * after clicking the link users will complete an online survey. the first page will give them basic information about the feeliv-covid survey and if they consent to participate, they will complete the survey. the decision to undertake the survey voluntarily, and will have no impact on their ongoing treatment. * informed consent will be obtained in the form of electronic name entry at the beginning of the survey. their name entry will be taken as an approval to allow the investigators data regarding their liver disease. only the following data will be taken from the patient's records: * child-turcotte-pugh (ctp) score * model for end stage liver disease (meld) score * etiology of liver dysfunction * no other data will be retrieved for the purpose of this study from patient's records.

Eligibility criteria:
inclusion criteria: - patients who have shown at institute of liver \& biliary sciences (ilbs) between 1st january 2018 and 31st march 2020 will be considered as currently being enrolled at ilbs for treatment. exclusion criteria: - incomplete questionnaires
il-38 evaluation as a biomarker in pediatric asthma

Conditions: Bronchial Asthma

Summary: the aim of this study is to investigate the associations between serum il-38 levels and different variables of asthma in children such as laboratory variables, pulmonary function test results, the diagnosis of asthma, and in correlation with disease severity.


Eligibility criteria:
inclusion criteria: * patients fulfilled the criteria of the global initiative for asthma (gina) * age group:6-14 years exclusion criteria: * malignancy * chronic inflammatory diseases
serum hbv rna value on chronic hepatitis b virus infection manage

Conditions: Chronic HBV Infection; Drug Withdrawal

Summary: as an alternative biomarker of intrahepatic covalently closed circular dna(cccdna) transcriptional activity, hepatitis b virus(hbv)rna may evolve during long-lasting virus-host interactionsduring chronic hepatitis b viral infection.the distribution pattern of serum hbv rna levels in the natural course of chronic hbv infection remains unclear. furthermore,serum hbv rna was associated with response to nas. so it may be another clinical surrogate marker for intrahepatic cccdna level after long-term nas treatment and be used to monitor nas therapy. the aim of this study was to evaluate thelevels of hbv rna during the natural courseof chb and the role in distinguishingthe natural phases of hbv infection and to investigate whether serum hbv rna level at the end of long-term nas treatment had a similar or better predict effect on off-therapy relapse than serum hbsag titer.


Eligibility criteria:
inclusion criteria: * 18 to 70 years old, * no gender restriction, * serum hbsag positive than 6 months, * can understand and sign informed consent, * good compliance. exclusion criteria: * coinfected with other hepatotropic virus such as hepatitis c virus,hepatitis d -virus,hepatitis e and hepatitis a etc; * coinfected with hiv, * markers such as ceruloplasmin, anti-nuclear antibodies and anti-mitochondrial antibodies for co-existent autoimmune and metabolic liver diseases were positive, * with hepatocellular carcinoma(hcc) * with uncontrollable extrehepatic disease, * received glucocorticoid or other immune inhibitor therapy, * pregnancy.

Keywords: hbv rna hbsag cccdna nucleos(t)ide analogue virological relapse
phase 1/2 study of an ocular sirolimus (rapamycin) formulation in patients with age-related macular degeneration

Conditions: Age-related Macular Degeneration; Choroidal Neovascularization

Summary: the purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration.


Eligibility criteria:
inclusion criteria include, but are not limited to: * diagnosed with sub-foveal choroidal neovascularization secondary to age-related macular degeneration * visual acuity of 20/50 to 20/200 in study eye exclusion criteria: * any other ocular disease that could compromise vision in the study eye * history of any prior treatment for choroidal neovascularization in the study eye * presence of other causes of choroidal neovascularization other than secondary to age-related macular degeneration

Keywords: wet amd cnv
a study investigating long-term treatment with spesolimab in people with a skin disease called hidradenitis suppurativa who completed a previous clinical trial

Conditions: Hidradenitis Suppurativa

Summary: this study is open to adults with hidradenitis suppurativa who took part in a previous clinical study of a medicine called spesolimab. participants who completed treatment can join this study. the purpose of this study is to find out how safe spesolimab is and whether it helps people with hidradenitis suppurativa in the long-term. participants are in this study for about 2 years and 4 months. for 2 years, participants visit the study site every 2 weeks to get spesolimab injections under the skin. at study visits, doctors check the severity of participants' hidradenitis suppurativa and collect information on any health problems of the participants.


Eligibility criteria:
inclusion criteria: * patients who have completed treatment in the parent hidradenitis suppurativa (hs) spesolimab trial (1368-0052) without premature discontinuation * signed and dated written informed consent in accordance with ich harmonized guideline for good clinical practice (ich-gcp) and local legislation prior to admission to the trial * woman of childbearing potential (wocbp) must be ready and able to use highly effective methods of birth control per ich m3 (r2) that result in a low failure rate of less than 1% per year when used consistently and correctly. a list of contraception methods meeting these criteria is provided in the patient information and consent form. exclusion criteria: * women who are pregnant, nursing, or who plan to become pregnant while in the trial * patients who experienced study treatment-limiting adverse events during the 1368-0052 parent trial * severe, progressive, or uncontrolled condition such as renal, hepatic, haematological, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease, or signs and symptoms thereof * any new documented active or suspected malignancy except appropriately treated basal cell carcinoma, squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix * use of any restricted medication or any drug considered by the investigator likely to interfere with the safe conduct of the study since the last visit of the 1368-0052 parent trial * history of allergy/hypersensitivity to the systemically administered trial medication agent or its excipients * major surgery (major according to the investigator's assessment) planned during this extension trial (e.g. hip replacement, aneurysm removal, stomach ligation), as assessed by the investigator * any condition which in the opinion of the investigator affects the safety of the patient, the patient's ability to participate in this trial or could compromise the quality of data further exclusion criteria apply
the anatomical location, cellular origin and molecular basis of gut-derived glucagon secretion

Conditions: Glucose Metabolism Disorders

Summary: delineation of the anatomical location, cellular origin and molecular basis of gut-derived glucagon secretion

aim: to delineate the anatomical origin, the molecular structure and precursors, the regulation and the (patho-) physiological implications of gut-derived glucagon. eight totally pancreatectomised patients, eight type 2 diabetes patients and eight healthy controls (age 18-80, bmi \ 6.5 - will be included. the participants will each undergo one screening day and one study day including a gastroduodenoscopy. multiple biopsies will be taken at several predefined locations in the upper gastrointestinal tract. these biopsies will be analysed with different techniques including immunohistochemical staining, quantitative polymerase chain reaction (qpcr-) analyses and more to search for glucagon. after the last biopsy has been collected, 50 g of glucose dissolved in 100 ml water is infused through the enteroscope into the most proximal part of the small intestine. hereafter blood samples for glucagon and gut hormone analyses will be collected 15, 30 and 45 min after the glucose infusion.

Eligibility criteria:
inclusion criteria: * normal kidney function, normal liver function, normal hemoglobin levels exclusion criteria: * diabetes type 1, first degree relatives with type 2 diabetes
safety and biologic activity study of gevokizumab to treat erosive osteoarthritis of the hand

Conditions: Osteoarthritis

Summary: the purpose of this proof-of-concept study is to determine whether gevokizumab is effective in the treatment of inflammatory erosive osteoarthritis of the hand.


Eligibility criteria:
inclusion criteria: * diagnosis of hand osteoarthritis * joint tenderness and/or redness * at least one erosion by x-ray (as determined by the central reader) * contraceptive measures adequate to prevent pregnancy during the study exclusion criteria: * history of inflammatory disease other than hand eoa including: secondary post-traumatic oa; rheumatoid arthritis; spondylarthropathies; erosion of the ulnar styloid process; psoriatic arthritis; skin psoriasis; erosions of the wrist; fibromyalgia * history of gout, pseudogout, or hemochromatosis * history of allergic or anaphylactic reactions to monoclonal antibodies * history of recurrent or chronic systemic infections * known allergy to acetaminophen * female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breast-feeding other protocol-defined inclusion/exclusion criteria may apply

Keywords: erosive osteoarthritis osteoarthritis osteoarthritis of the hand
agreement between laterality of tsui test and laterality of color flow doppler signals during labor epidural analgesia

Conditions: Labor Pain

Summary: epidural analgesia for relief of labor pain is a very common, safe and reliable technique that requires placement of a catheter in the epidural space. about 5% of labor epidural catheters may need to be re-sited due to failure of analgesia. this is often caused by malposition of the epidural catheter. many factors may influence the position of the tip of the epidural catheter and the resulting spread of local anesthetic solution within the epidural space and consequently the quality of labor pain management. the electrical stimulation of the epidural catheter, commonly known as tsui test, can reliably confirm its positioning within the epidural space if this stimulus produces a muscular twitch under a certain current amplitude threshold. this muscular response is unilateral in 90% of the cases, not having any relationship between unilaterality and unsatisfactory catheter performance. it is unknown if this unilateral response has any correlation with the actual position of the catheter tip in terms of right or left side of the epidural space. furthermore, the tsui test does not give any information on the spread of anesthetic solution into the epidural space. recent investigation shows that color flow doppler ultrasound during fluid injection through the epidural catheter may be helpful in determining the laterality of the tip of the epidural catheter; furthermore it may be able to inform about the spread the anesthetic solution, which is a limitation of the tsui test. the investigators will perform an observational study to investigate the response patterns of tsui test and color flow doppler ultrasound in the obstetric population. women who have delivered under epidural analgesia will be approached for the study before the epidural catheter is removed. the investigators aim to characterize the laterality and current thresholds of tsui test response and the laterality of the lumbar epidural catheter tip by color doppler ultrasound. the investigators hope to describe the findings and to correlate them with other clinical outcomes.


Eligibility criteria:
inclusion criteria: * patients who have delivered vaginally under epidural anesthesia exclusion criteria: * patients who refuse, are unable to give or have withdrawn consent * patients unable to communicate fluently in english. * patients who experience fetal or maternal complications during delivery.

Keywords: epidural catheter epidural analgesia labor epidural ultrasound doppler tsui test
evaluation of thermographic images of the knee in patients with anterior cruciate ligament reconstruction outcome

Conditions: ACL Injury

Summary: the thermo-lca study is a diagnostic interventional study for assessment of knee temperature of asymptomatic patients with acl reconstruction compared with unoperated healthy contralateral knee. the aim of the study is to analyze thermographic images obtained from the knees of asymptomatic patients with acl reconstruction that occurred between the previous 2 and 5 years, to assess the presence of inflammation in the knee with reconstructed acl compared with the contralateral.

thermo-lca study involves recruitment of thirty volunteers with unilateral acl reconstruction will be enrolled subjects aged 18 to 40 years, with no history of previous surgery or chronic gonalgia in the contralateral knee. once the patient's informed consent has been obtained, the patient will wait sitting 10 minutes inside the temperature-controlled room of 23°c, a thermographic assessment will then be performed using a flirt1020 thermal imaging camera. photographs will be acquired in anteroposterior, right lateral, left lateral, and posteroanterior views of both knees. the patient will then perform a knee flexion-extension exercise against resistance for 2 minutes using a 2 kg weighted ankle monitor. the speed at which this exercise is performed will be constant for all subjects, with one repetition per second per leg. following this exercise, four more thermographic images identical to the first will be acquired. basal thermographic assessments will be performed at 5', 10' and 20' minutes after the end of the exercise.once the images are acquired these will be analyzed using researchir software, regions of interest of the knees will then be constructed and their temperature change over the various acquisitions and how it changes after physical exertion will then be analyzed.

Eligibility criteria:
inclusion criteria: 1. male or female patients aged between 18 and 40 years; 2. asymptomatic at the time of evaluation (ikdc ≥95); 3. no history of previous surgery or contralateral knee fractures; 4. no history of direct or indirect trauma in the previous six months to either knee; 5. absence of gonalgia (vas pain equal to 0) at evaluation; 6. bmi between 18.5 kg/m2 and 29.9 kg/m2. exclusion criteria: 1. patients who are incapacitated or have neurological disorders that may invalidate the research protocol; 2. diagnosis of leukemia, known presence of metastatic malignant cells, current or planned chemotherapy; 3. diagnosis of rheumatoid arthritis, reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis or arthritis resulting from another inflammatory disease; human immunodeficiency virus (hiv) infection, viral hepatitis; chondrocalcinosis; 4. patients with uncontrolled diabetes mellitus; 5. patients with uncontrolled thyroid metabolic disorders; 6. patients abusing alcoholic beverages, drugs, or medications;

Keywords: acl reconstruction anterior cruciate ligament infrared thermography joint inflammation
study evaluating the safety and efficacy of onartuzumab and/or bevacizumab in combination with paclitaxel in participants with metastatic, triple negative breast cancer

Conditions: Breast Cancer

Summary: this is a randomized, phase ii, double-blind, multicenter, placebo-controlled trial designed to preliminarily estimate the efficacy and evaluate the safety and tolerability of onartuzumab (metmab) + bevacizumab + paclitaxel and onartuzumab + placebo + paclitaxel versus placebo + bevacizumab + paclitaxel in participants with metastatic or locally recurrent, triple-negative breast cancer who either have not received treatment (first-line) or have progressed after one conventional cytotoxic chemotherapy regimen (second-line).


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0 or 1 * histologically confirmed estrogen receptor (er)-, progesterone receptor (pr)-, and human epidermal growth factor 2 (her2)-negative (triple-negative) adenocarcinoma of the breast * confirmed availability of tumor tissue exclusion criteria: * prior therapy with two or more regimens for metastatic breast cancer * any systemic anti-cancer therapy within 3 weeks prior to day 1 of cycle 1 * major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to day 1 of cycle 1 * prior therapy with a taxane for metastatic breast cancer * prior therapy with bevacizumab, sorafenib, sunitinib, or other putative vascular endothelial growth factor (vegf) pathway-targeted therapy following diagnosis of breast cancer * prior therapy with hormones and/or trastuzumab * inadequate hematology, renal, or hepatic organ function bevacizumab exclusion criteria: * uncontrolled hypertension (systolic pressure greater than \[\>\] 150 millimeters of mercury \[mmhg\] and/or diastolic pressure \> 100 mmhg), with or without anti-hypertensive medication * evidence of bleeding diathesis or coagulopathy
evaluate the efficacy and safety of kk8398 in patients with achondroplasia（aoba study）

Conditions: Achondroplasia

Summary: this trial will evaluate the efficacy of kk8398 on annualized height velocity after 52 weeks of repeated administration of kk8398 to patients with achondroplasia


Eligibility criteria:
inclusion criteria: 1. patients who are between 2.5 and 17.5 years old of age at the time of provisional registration. patients who meet certain criteria in terms of tanner stage and bone age. 2. patients who have been diagnosed with achondroplasia through genetic testing. exclusion criteria: 1. patients who meet the criteria for a certain height determined by age and gender in the "growth chart for patients with achondroplasia" at the time of the pre-registration examination 2. patients who have received treatment with r-hgh or a cnp analogue within a certain period prior to the pre-enrollment examination. 3. patients who have had previous osteotomy or who are scheduled to undergo osteotomy or epiphyseal growth inhibition during the study period. epiphyseal growth inhibition in which the plate was removed more than 26 weeks prior to the pre-registration examination will not be excluded if the patient has completely healed without sequelae, based on the judgment of the investigator or sub-investigator.
metformin compared to glyburide in gestational diabetes

Conditions: Gestational Diabetes

Summary: our hypothesis is that metformin and glyburide will have equal efficacy in controlling blood glucose in gestational diabetics with no increase in adverse maternal, fetal or neonatal outcomes.

pregnant women are screened with a one hour 50g glucose challenge. women with values of 130 mg/dl or greater are then given a 100g glucose tolerance test. two abnormal values are diagnostic of gestational diabetes. all women are initially counseled on diet and exercise. women who fail to maintain a fasting of \<105mg/dl and 2 hr postprandial \< 120 mg/dl are offered participation in the study. women were randomized to either metformin or glyburide via a computer generated randomization. women who fail to meet glycemic goals after receiving the maximum dose of study medication were considered treatment failures and insulin therapy was initiated.

Eligibility criteria:
inclusion criteria: * gestational diabetes not controlled with diet and exercise exclusion criteria: * history of alcohol misuse * history of drug misuse * chronic hypertension requiring medication * renal failure * hepatic disease or dysfunction * known fetal anomaly * inability to give consent * known allergy to metformin or glyburide

Keywords: gestational diabetes metformin glyburide oral agents
optimum hand position during cardiopulmonary resuscitation

Conditions: Cardiopulmonary Resuscitation; Hand Position

Summary: the almost evidences of the optimal hand position during compression had been based on chest computed tomography (ct) or chest plain films of patients for investigating the effective location for compressing the left ventricle of the heart during cardiopulmonary resuscitation (cpr). however every study was conducted at full inspired state of respiration. a prospective cohort study to evaluate the proper hand position during cpr based on expired respiratory state ct as the health screening would be needed.


Eligibility criteria:
inclusion criteria: * over 18 years of age * no history of heart or lung disease * no history of chest or abdominal surgery exclusion criteria: * abnormal findings in ldct, which might influence inspiration or expiration, were excluded after image interpretation by the board certified radiologists
the role of zamzam water in idiopathic oligohydramnios

Conditions: Oligohydramnios

Summary: the aim of this study is to evaluate the efficacy of drinking zamzam water versus tap water in increasing the af index in women with oligohydramnios.

oligohydramnios refers to decrease in amniotic fluid and it is defined as a deepest fluid pocket of less than 2 cm or an amniotic fluid index of 5 cm or less. oligohydramnios complicates 0.5% to 8% of pregnancies, and 12 % if postdates when it occurs in first half of pregnancy it is associated with birth defects while in second half it causes poor fetal growth, malpresentations , fhr decelerations , mas , fetal suicidal syndrome and increases cesarean section and management and prognosis depend on gestational age

Eligibility criteria:
inclusion criteria: * pregnant female with idiopathic oligohydramnios exclusion criteria: * patients with medical disorder * congenital anomalies * premature rupture of membrane * patient refuse to participate